Abstract:Objective To compare the betatrophin levels in patients with coronary disease and controls so as to figure out its relationships with factors related to glucose and lipid metabolisms Methods Subjects were divided into 2 groups, i.e. coronary group (n = 107) and control group (n = 35). Based on the levels of glycosylated hemoglobin A1c (HbA1c), the coronary group was divided into normal-HbA1c and increased-HbA1c subgroups. Other clinical indexes were examined by automatic analysis, which included triglyceride (TG), total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), creatinine (Scr), uric acid (UA), high-sensitivity C-reactive protein (hsCRP), brain natriuretic peptide (BNP) and homocysteine (Hcy). Results Compared to the coronary group, plasma betatrophin level was lowered by 26.6% in the control group (P = 0.040). Betatrophin level of the normal-HbA1c subgroup decreased by 33.0% (P = 0.001) compared with the control group, whereas betatrophin level in the increased-HbA1c subgroup increased by 22.6% compared to the normal-HbA1c subgroup (P = 0.020). Plasma betatrophin level was positively correlated with HbA1c level in the coronary group (r = 0.223, P = 0.021). In the coronary group, the male patients had significantly lower betatrophin levels than the female patients [(0.149 ± 0.068) vs (0.181 ± 0.078) ng/ml, P = 0.028]. Conclusions Betatrophin may be a new factor correlating to glucose and TG metabolisms in patients with coronary disease.